Study #2014-0279
Phase II Study Assessing the Effect of BK Specific CTL Lines Generated by Ex Vivo Expansion in Stem Cell Transplant Recipients with BK Infection and JC Virus Infection
MD Anderson Study Status
Enrolling
Treatment Agent
Allogeneic BK-specific Cytotoxic T-lymphocytes
Description
This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and/or JC virus.
Information and next steps
Disease:
Acquired Immunodeficiency Syndrome, BK Virus Infection, Human Immunodeficiency Virus, JC Virus Infection, Malignant Neoplasm, Merkel Cell Carcinoma, Merkel Cell Polyomavirus Infection, Viral Encephalitis
Study phase:
II
Physician name:
Amanda Olson
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.